NCT00347672View on ClinicalTrials.gov

Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
InfluenzaVirus Diseases
Interventions
BIOLOGICAL

H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)

Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)

Trial Locations (1)

21205

Center of Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health, Baltimore

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00347672 - Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults | Biotech Hunter | Biotech Hunter